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Abstract 
Melatonin is a hormone that is mainly secreted by the pineal gland and exhibits a wide 
spectrum of activities, including antioxidant functions. Melatonin has been detected in 
gingival crevicular fluid. However, the role of melatonin in periodontal tissue is still 
uncertain. The aim of this study was to examine the effects of melatonin on inflammatory 
mediator expression in human periodontal ligament cells (HPDLC).  
Interleukin (IL)-1β induced CXC chemokine ligand (CXCL)10, matrix metalloproteinase 
(MMP)-1, and tissue inhibitors of metalloproteinase (TIMP)-1 production in HPDLC. 
Melatonin decreased CXCL10 and MMP-1 production and increased TIMP-1 production in 
IL-1β-stimulated HPDLC. Western blot analysis showed that melatonin inhibited p38 
mitogen-activated protein kinase (MAPK) and c-jun N-terminal kinase (JNK) 
phosphorylation, and IκB-α degradation and phosphorylation in IL-1β-stimulated HPDLC. 
These results suggest that melatonin might inhibit Th1 cell migration by reducing CXCL10 
production. Moreover, melatonin might inhibit soft tissue destruction by decreasing MMP-1 
production in periodontal lesions.  
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Introduction  
Periodontitis is characterized by gingival inflammation, inflammatory cell infiltration, and 
alveolar bone loss caused by the interaction of host defense mechanisms with a subset of 
microorganisms that colonize the subgingival environment. Previous reports have revealed 
that the immune reactions that occur in periodontal lesions are involved in the initiation and 
progression of periodontal disease [1,2].  
CXC chemokine ligand 10 (CXCL10) is a chemokine that plays a role in the 
immunopathogenesis of inflammatory diseases, such as rheumatoid arthritis [3] and 
periodontal disease [4]. CXCL10 binds to its receptor, CXC chemokine receptor 3 (CXCR3), 
and regulates immune responses by activating and recruiting immune cells, including Th1 
cells [5]. It is reported that Th1 cells are involved in the exacerbation of periodontal disease 
[2]. Therefore, we previously examined whether resident periodontal cells produce CXCL10. 
We reported that certain cytokines induced CXCL10 production in human gingival 
fibroblasts [6]. However, we did not determine whether there are any factors that can 
suppress CXCL10 production in periodontal lesions. 
Matrix metalloproteinase-1 (MMP-1) is one of the key proteolytic enzymes that degrade 
types I and III collagen, which are the predominant types of collagen in periodontal tissue. 
Therefore, MMP-1 might play an important role in destroying periodontal tissue in 
inflammatory lesions [7]. Tissue inhibitors of metalloproteinase (TIMP) are endogenous 
inhibitors of MMP. Therefore, the ratio of MMP to TIMP has an important influence on 
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matrix degradation in inflammatory tissues.  
Melatonin, a natural pineal secretory product, is well known for its important functions in 
circadian rhythm regulation [8], cancer inhibition [9], and seasonal rhythmicity [10]. In 
addition, melatonin also has broader functions including antioxidant [11] and 
immunomodulatory roles [12]. However, the effects of melatonin on cytokine expression in 
periodontal resident cells are unclear. 
The aim of this study was to examine the influence of melatonin on CXCL10, MMP-1, and 
TIMP-1 production in IL-1β-stimulated human periodontal ligament cells (HPDLC), which 
are the major resident cells in periodontal tissues. Moreover, we investigated whether 
melatonin treatment modified the activation of the nuclear factor (NF)-κB and 
mitogen-activated protein kinase (MAPK) pathways in IL-1β-stimulated HPDLC. 
Materials and Methods 
Cell culture 
HPDLC were obtained from Lonza Walkersville Inc. (Walkersville, MD, USA) and grown in 
Dulbecco’s modified Eagle medium (Gibco, Grand Island, NY) supplemented with 10% fetal 
bovine serum (JRH Biosciences, Lenexa, KS), 1 mmol/L sodium pyruvate (Gibco), and 
antibiotics (penicillin G: 100 units/ml, streptomycin: 100 µg/ml) at 37OC in humidified air 
with 5% CO2. The cells were used between passage numbers 5 and 10. 
CXCL10, MMP-1, and TIMP-1 production in HPDLC 
The HPDLC were stimulated with recombinant human IL-1β (Peprotech, Rocky Hill, NJ, 
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USA) for 24 hours. The supernatants were collected, and their CXCL10, MMP-1, and 
TIMP-1 concentrations were examined in triplicate using enzyme-linked immunosorbent 
assays (ELISA). DuoSet kits (R&D systems, Minneapolis, MN, USA) were used to obtain 
the CXCL10, MMP-1, and TIMP-1 measurements. All assays were performed according to 
the manufacturer’s recommendations, and CXCL10, MMP-1, and TIMP-1 levels were 
determined using the standard curve prepared for each assay. In selected experiments, the 
HPDLC were cultured for 1 hour in the presence or absence of melatonin (Cayman Chemical, 
Ann Arbor, MI, USA), SB203580 (20 µM; Santa Cruz Biotechnology, Santa Cruz, CA, 
USA), SP600125 (20 µM; Enzo Life Sciences, Plymouth Meeting, PA, USA), or SC514 (20 
µM; Enzo Life Sciences) prior to their incubation with IL-1β. Melatonin, SB203580, 
SP600125, and SC514 were dissolved in dimethyl sulfoxide (DMSO) and diluted at least 1 : 
2000 in culture media before use. The 2000 times dilution of DMSO had no effect on the 
viability of the cells.  
Western blot analysis 
To detect the IL-1β-induced phosphorylation of signal transduction molecules, Western blot 
analysis was performed. HPDLC were stimulated with IL-1β (1 ng/ml) for 15, 30, or 60 
minutes after being pretreated (or not) with melatonin (100 µM or 1000 µM) for 1 hour. Then, 
the cells were washed once with ice-cold phosphate-buffered saline, before being incubated 
on ice for 10 minutes with cell lysis buffer (Cell Signaling Technology, Danvers, MA, USA) 
supplemented with protease inhibitor cocktail (Sigma). After removing any debris by 
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centrifugation, the total protein concentrations of the lysates were quantified using the 
Bradford protein assay. Then, 20-µg protein samples were fractionated on a 4-20% sodium 
dodecyl sulfate polyacrylamide gel electrophoresis gel, before being transferred to 
polyvinylidene difluoride membranes. The membranes were blocked for 1 hour with 1% 
non-fat dried milk at room temperature and then incubated with phospho-IκB-α mouse 
monoclonal antibody (Cell Signaling Technology), phospho-p38 MAPK rabbit monoclonal 
antibody (Cell Signaling Technology), phospho-extracellular signal-regulated kinase (ERK) 
rabbit monoclonal antibody (Cell Signaling Technology), phospho-c-jun N-terminal kinase 
(JNK) rabbit monoclonal antibody (Cell Signaling Technology), p38 MAPK rabbit 
monoclonal antibody (Cell Signaling Technology), ERK rabbit monoclonal antibody (Cell 
Signaling Technology), JNK rabbit monoclonal antibody (Cell Signaling Technology), IκB-α 
mouse monoclonal antibody (Cell Signaling Technology), or GAPDH rabbit monoclonal 
antibody (Cell Signaling Technology) overnight at 4 OC followed by an appropriate secondary 
horseradish peroxidase-conjugated antibody (Sigma) for 1 hour at room temperature. Protein 
bands were visualized using the ECL Prime Western blotting detection system (GE 
Healthcare, Uppsala, Sweden). Each chemiluminescent signal was quantified using the 
ImageJ software (version 1.44). 
Statistical analysis 
Statistical analyses were performed using the Student’s t test. P values of <0.05 were 
considered significant in Figs. 1 and 4. 
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Results 
Effects of melatonin on CXCL10, MMP-1, and TIMP-1 release from IL-1β-stimulated 
HPDLC  
It has been reported that IL-1β induces CXCL10, MMP-1, and TIMP-1 production in 
HPDLC [13]. Therefore, we first examined if melatonin is able to modulate CXCL10, 
MMP-1, or TIMP-1 production. As shown in Fig. 1, melatonin treatment decreased both 
CXCL10 and MMP-1 production in IL-1β-stimulated HPDLC in a dose-dependent fashion. 
On the other hand, melatonin (1000 µM) increased TIMP-1 production in IL-1β-treated cells.  
Effects of melatonin on MAPK phosphorylation in IL-1-β-stimulated HPDLC 
Next, we investigated the effects of melatonin on MAPK phosphorylation in IL-1-β-treated 
HPDLC because it is known that IL-1-β activates MAPK pathways in HPDLC [14,15]. Fig. 2 
shows that 1000 µM melatonin inhibited p38 MAPK and JNK phosphorylation in HPDLC 
after 60 minutes' IL-1β-stimulation. 
Effects of melatonin on IκB-α phosphorylation and degradation in IL-1β-stimulated 
HPDLC 
Next, we examined the effects of melatonin on NF-κB pathway activation in 
IL-1β-stimulated HPDLC because it is known that IL-1β strongly activates the NF-κB 
pathway in HPDLC [16]. Fig. 3 shows that melatonin (100 µM and 1000 µM) markedly 
inhibited IκB-α phosphorylation and degradation in IL-1β-stimulated HPDLC.  
Effects of p38 MAPK, JNK, and NF-κB inhibitors on CXCL10, MMP-1, and TIMP-1 
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production in IL-1β-stimulated HPDLC  
Figs. 2 and 3 show that melatonin inhibited p38 MAPK, JNK, and NF-κB activation in 
HPDLC that had been stimulated with IL-1β. Next, we examined whether p38 MAPK, JNK, 
or NF-κB are involved in CXCL10, MMP-1, or TIMP-1 release from IL-1β-stimulated 
HPDLC using inhibitors. Fig. 4 shows that the p38 MAPK, JNK, and NF-κB inhibitors 
significantly inhibited CXCL10 production in IL-1β-treated HPDLC. On the other hand, the 
p38 MAPK inhibitor did not modulate MMP-1 release from HPDLC although the JNK and 
NF-κB inhibitors markedly suppressed MMP-1 production in IL-1β-stimulated HPDLC. 
None of the inhibitors had any effect on TIMP-1 production in IL-1β-treated cells. 
Discussion 
In this study, we demonstrated, for the first time, the anti-inflammatory effects of melatonin 
on HPDLC.  
Previous studies examined the expression of melatonin in periodontal tissue. Srinath et al. 
reported that melatonin was expressed in gingival crevicular fluid, and the level of melatonin 
was lower in subjects with periodontal disease than in healthy subjects [17]. Similarly, 
Almughrabi et al. found that the melatonin levels in gingival crevicular fluid and saliva were 
lower in patients with chronic periodontitis or aggressive periodontitis than in those with 
gingivitis and healthy subjects [18]. They suggested that melatonin might have a protective 
role against periodontal disease. We consider that the anti-inflammatory effects of melatonin 
might be important for the initiation and progression of periodontal disease. 
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Various researchers have described the anti-inflammatory effects of melatonin on periodontal 
resident cells. Choi et al. reported that melatonin inhibited nitric oxide and IL-6 production in 
Prevotella intermedia, which is a major cause of inflammatory reactions in periodontal 
tissue,-stimulated murine macrophages [19]. Gómez-Florit et al. demonstrated that melatonin 
treatment inhibited MMP-1 and IL-6 production in non-stimulated human gingival fibroblasts 
[20]. The above results and our findings show that melatonin modulates the 
anti-inflammatory effects of various kinds of cells in periodontal lesions and suppresses the 
progression of periodontal inflammation.  
There have only been a few in vitro studies about the effects of melatonin on CXCL10 
production. Ban et al. reported that microarray analysis showed that melatonin inhibited 
CXCL10 mRNA expression in lipopolysaccharide(LPS)-activated RAW 264.7 macrophages, 
which agrees with our findings [21]. Melatonin might inhibit Th1 cell migration and 
accumulation, and hence, inhibit CXCL10 production by resident periodontal cells and 
immune cells in diseased periodontal tissue. 
There have been several reports about the effects of melatonin on MMP and TIMP expression. 
Qin et al. reported that melatonin inhibited MMP-9 production by IL-1β-stimulated human 
umbilical vein endothelial cells [22], and Esposito et al. found that the activity and expression 
of MMP-9 and MMP-2 were reduced by melatonin during experimental colitis [23]. Recently, 
Gómez-Florit et al. demonstrated that melatonin treatment inhibited MMP-1 production and 
enhanced TIMP-1 expression in non-stimulated human gingival fibroblasts [20]. They did not 
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examine the effects of melatonin on cytokine or bacteria-stimulated gingival fibroblasts. 
However, taking these results together with our findings it is suggested that melatonin 
prevents tissue degradation by inhibiting MMP-1 production and increasing TIMP-1 
production in gingival fibroblasts and periodontal ligament cells in diseased periodontal 
tissue.  
Some previous studies examined the effects of melatonin on MAPK activation. Shin et al. 
reported that melatonin markedly decreased the phosphorylation of MAPK, including p38 
MAPK, ERK, and JNK, induced by epidermal growth factor stimulation in human airway 
epithelial cells [24]. On the other hand, Xia et al. showed that it had no effect on Toll-like 
receptor 4-mediated phosphorylation of p38 MAPK, ERK, and JNK in LPS-stimulated RAW 
264.7 macrophages [25]. In the current study, we demonstrated that melatonin inhibited p38 
MAPK and JNK activation, whereas ERK phosphorylation was not affected by melatonin 
treatment in IL-1β-stimulated HPDLC. We consider that the effects of melatonin on MAPK 
activation are dependent on the type of cells and stimulants involved. 
Previous reports have described the effects of melatonin on NF-κB activation. Xiao et al. 
reported that melatonin inhibited IκB-α degradation in LPS-stimulated RAW264.7 
macrophages [25]. Qin et al. found that melatonin inhibited the nuclear translocation of 
NF-κB p65 in IL-1β-stimulated human umbilical vein endothelial cells [22]. Taking these 
results together with ours, it is suggested that melatonin decreases inflammatory mediator 
expression by suppressing NF-kB activation in certain types of cells, including macrophages, 
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endothelial cells, and mesenchymal cells.  
The present study demonstrated that melatonin suppressed IL-1β-induced CXCL10 and 
MMP-1 production, and enhanced TIMP-1 production in HPDLC. In addition, we revealed 
that melatonin inhibited p38 MAPK and JNK phosphorylation and IκB-α degradation in 
IL-1β-stimulated HPDLC. These results indicate that melatonin inhibits the initiation and 
progression of periodontal disease by controlling chemokine, MMP, and TIMP production in 
periodontal lesions. 
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Figure legends 
Fig. 1. Effects of melatonin on CXCL10, MMP-1, and TIMP-1 production in 
IL-1β-stimulated HPDLC 
 HPDLC were treated with melatonin (1, 10, 100, or 1000 µΜ) for 1 hour, before being 
stimulated with IL-1β (1 ng/ml). The supernatants were collected after 24 hours' incubation. 
The concentrations of CXCL10, MMP-1, and TIMP-1 in the supernatants were assessed 
using ELISA. The results are shown as the mean and SD of one representative experiment 
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performed in triplicate. The error bars represent SD values. * = P<0.05, significantly different 
from the IL-1β-stimulated HPDLC that were not pretreated with melatonin 
Fig. 2. Effects of melatonin on IL-1β-induced p38 MAPK, ERK, and JNK 
phosphorylation in HPDLC 
 The cultured cells were treated with melatonin (100 or 1000 µM) for 60 min and then 
stimulated with 1 ng/ml IL-1β for 15, 30, or 60 min. The cells were lysed in lysis buffer 
containing protease inhibitors, and the phosphorylation of p38 MAPK, ERK, and JNK was 
assessed using Western blot analysis. A representative Western blot that shows the 
phospho-p38 MAPK, total p38 MAPK, phospho-ERK, total ERK, phospho-JNK, and total 
JNK levels detected in the HPDLC during three independent experiments is shown. The bar 
graphs of phospho-p38 MAPK, phospho-ERK, and phospho-JNK expression were 
normalized to total p38 MAPK, total ERK, and total JNK, respectively. 
Fig. 3. Effects of melatonin on IL-1β-induced IκB-α phosphorylation and degradation 
The cultured cells were pretreated with melatonin (100 or 1000 µM) for 60 min and then 
stimulated with 1 ng/ml IL-1β for 15, 30, or 60 min. The cells were lysed in lysis buffer 
containing protease inhibitors, and the phosphorylation and degradation of IκB-α were 
assessed using Western blot analysis. A representative Western blot that indicates the 
phospho-IκB-α, total IκB-α, and GAPDH levels detected in the HPDLC during three 
independent experiments is shown. The bar graphs of phospho-IκB-α or total 
IκB-α expression were normalized to GAPDH. 
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Fig. 4. Effects of signal transduction inhibitors on IL-1β-stimulated CXCL10, MMP-1, 
and TIMP-1 release by HPDLC 
 The cells were pre-incubated with SB203580 (20 µM), SP600125 (20 µM), or SC514 (20 
µM) for 1 hour and then incubated with IL-1β (1 ng/ml). After 24 hours' incubation, the 
supernatants were collected, and their CXCL10, MMP-1, and TIMP-1 levels were measured 
using ELISA. The results are shown as the mean and SD of one representative experiment 
performed in triplicate. The error bars show the SD of the values. * = P<0.01 significantly 
different from the IL-1β-stimulated HPDLC that were not treated with inhibitors 
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